Monitoring Drug Efficacy in Patients with Alzheimer's Disease
ConditionAlzheimer Disease
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age65+
SponsorUniversity of the Philippines
About this trial
This study will explore the different factors associated with drug response to acetylcholinesterase (AChE) inhibitor (donepezil) and NMDA receptor antagonist (memantine) in patients with Alzheimer's Disease.
Eligibility criteria
Qualifiers
newly diagnosed with mild or moderate dementia using the Montreal Cognitive Assessment and Clinical Dementia Rating (CDR) performed by a licensed psychometrician
clinically diagnosed by an expert adult neurologist as having probable AD using the National Institute of Neurological and Communicative Disorders and Stroke and Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria
treatment naive for any acetylcholinesterase inhibitors or memantine OR those who have not taken any acetylcholinesterase inhibitors or memantine in the last three months for any reasons except for adverse drug reaction
age 65 years old
Disqualifiers
with structural or vascular causes of dementia other than subcortical lacunes (2 or less) as seen in plain CT scan
dementia diagnosis other than AD as determined by an expert adult neurologist
with untreated depression or related psychiatric disorders in the last 6 months
use of systemic antibotics in the previous three months prior to providing fecal specimens
Trial design
Treatments tested in this trial
- AChE inhibitor monotherapy
- AChE inhibitor and NMDA receptor antagonist combination therapy
Treatment groups
60 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov